{"hands_on_practices": [{"introduction": "The success of any Chimeric Antigen Receptor (CAR) T cell therapy depends on its ability to recognize and eliminate tumor cells, which can express target antigens at highly variable levels. This exercise explores the fundamental biophysical relationship between the density of antigens on a target cell, the binding affinity of the CAR, and the internal signaling threshold required for T cell activation [@problem_id:5035133]. By deriving the minimum antigen density needed to trigger a response, you will gain a quantitative appreciation for a CAR's intrinsic sensitivity and appreciate how \"armored\" CAR designs can be engineered to effectively combat tumors with low antigen expression.", "problem": "A Chimeric Antigen Receptor (CAR) T cell targeting a solid tumor antigen is engineered with next-generation features, including an armored design that modulates downstream signaling to resist inhibitory cytokines. At the immunological synapse, receptor engagement follows a mass-action binding equilibrium that yields the standard receptor occupancy relation $r(n) = \\frac{n}{n + K_D}$, where $n$ is the antigen density at the synapse (in molecules per cell or equivalent surface density units) and $K_D$ is the effective equilibrium dissociation constant expressed in the same units as $n$. Assume that productive activation of CAR signaling requires the occupancy to exceed a threshold determined by the downstream network, so that $r(n) \\ge \\theta$ for some $0  \\theta  1$.\n\nStarting from the principles of mass-action binding and the definition of an equilibrium dissociation constant, and without invoking any shortcuts beyond the occupancy definition $r(n)$ above, derive the closed-form analytic expression for the minimum antigen density $n_{\\min}$ required for activation as a function of $K_D$ and $\\theta$. Then interpret how this dependency constrains CAR design for typical solid tumor antigen densities, using as a realistic reference range $n \\in [10^{4}, 10^{6}]$ molecules per cell for many solid tumors and acknowledging that armored CARs can effectively lower $\\theta$ by strengthening costimulation or insulating signaling from inhibitory cues. Your derivation should clearly state any assumptions used and justify algebraic steps based on the stated base principles.\n\nProvide the final expression for $n_{\\min}$ only. Do not include any units in the final expression. No numerical evaluation is required in the final answer; any qualitative interpretation should be included in your reasoning but not in the final expression.", "solution": "The problem is first subjected to validation.\n\n### Step 1: Extract Givens\n-   Receptor occupancy relation: $r(n) = \\frac{n}{n + K_D}$\n-   $n$: antigen density at the synapse.\n-   $K_D$: effective equilibrium dissociation constant.\n-   Condition for productive activation: $r(n) \\ge \\theta$.\n-   $\\theta$: activation threshold, where $0  \\theta  1$.\n-   Objective: Derive the closed-form analytic expression for the minimum antigen density, $n_{\\min}$.\n-   Contextual information: A realistic reference range for $n$ is $[10^{4}, 10^{6}]$ molecules per cell for many solid tumors. Armored CARs can effectively lower $\\theta$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed for validity based on the provided criteria.\n\n-   **Scientifically Grounded**: The problem utilizes the standard mass-action binding model, often represented by the Hill-Langmuir equation, which is fundamental in biochemistry and pharmacology for describing receptor-ligand interactions. The concept of a signaling threshold ($\\theta$) is a cornerstone of cell biology. The application to Chimeric Antigen Receptor (CAR) T cells, antigen density, and the effect of 'armoring' is contemporary, realistic, and highly relevant to the field of translational medicine. The problem is scientifically sound.\n-   **Well-Posed**: The problem asks for the minimum antigen density, $n_{\\min}$, that satisfies a given inequality. The function $r(n)$ is a monotonically increasing function of $n$ for $n \\ge 0$. Therefore, solving the inequality $r(n) \\ge \\theta$ for $n$ will yield a lower bound, and a unique minimum value $n_{\\min}$ exists. The problem is well-posed.\n-   **Objective**: The problem is stated using precise, standard scientific terminology ($K_D$, receptor occupancy, antigen density). It is free of subjective or ambiguous language.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. It is scientifically grounded, well-posed, and objective. A solution will be derived.\n\n### Derivation\nThe problem requires the derivation of the minimum antigen density, $n_{\\min}$, required for the activation of a CAR T cell. The condition for activation is given as a threshold on the receptor occupancy, $r(n)$.\n\nThe activation condition is:\n$$r(n) \\ge \\theta$$\n\nThe receptor occupancy, $r(n)$, is defined by the mass-action binding equilibrium:\n$$r(n) = \\frac{n}{n + K_D}$$\nwhere $n$ is the antigen density and $K_D$ is the equilibrium dissociation constant.\n\nSubstituting the definition of $r(n)$ into the activation condition yields the inequality:\n$$\\frac{n}{n + K_D} \\ge \\theta$$\n\nThe goal is to solve this inequality for $n$. We are looking for the minimum value of $n$, denoted $n_{\\min}$, that satisfies this condition. This minimum will occur at the boundary of the inequality, where equality holds. However, we will solve the inequality generally first to demonstrate that a minimum is the correct interpretation.\n\nWe can multiply both sides of the inequality by the denominator, $(n + K_D)$. It is a necessary physical assumption that both antigen density $n$ and the dissociation constant $K_D$ are non-negative quantities. Specifically, $n \\ge 0$ and $K_D  0$. Therefore, their sum, $(n + K_D)$, is strictly positive for any relevant biological scenario ($n  0$). Multiplying by a positive quantity does not change the direction of the inequality:\n$$n \\ge \\theta (n + K_D)$$\n\nDistributing $\\theta$ on the right-hand side gives:\n$$n \\ge \\theta n + \\theta K_D$$\n\nTo solve for $n$, we gather all terms containing $n$ on one side of the inequality:\n$$n - \\theta n \\ge \\theta K_D$$\n\nFactoring out $n$ on the left-hand side:\n$$n(1 - \\theta) \\ge \\theta K_D$$\n\nThe final step is to isolate $n$ by dividing by $(1 - \\theta)$. The problem states that the threshold $\\theta$ is constrained such that $0  \\theta  1$. This implies that the term $(1 - \\theta)$ is strictly positive. Therefore, dividing by $(1 - \\theta)$ does not alter the direction of the inequality:\n$$n \\ge \\frac{\\theta K_D}{1 - \\theta}$$\n\nThis inequality specifies that for activation to occur, the antigen density $n$ must be greater than or equal to the expression on the right-hand side. The minimum antigen density, $n_{\\min}$, is therefore precisely the value at the lower bound of this range:\n$$n_{\\min} = \\frac{\\theta K_D}{1 - \\theta}$$\n\nThis provides the closed-form analytic expression for the minimum required antigen density as a function of the dissociation constant $K_D$ and the activation threshold $\\theta$.\n\n### Interpretation\nThe derived expression $n_{\\min} = \\frac{\\theta K_D}{1 - \\theta}$ reveals how CAR design parameters and target cell characteristics determine activation sensitivity.\n1.  **Dependence on $K_D$**: $n_{\\min}$ is directly proportional to $K_D$. A higher $K_D$ corresponds to lower binding affinity, meaning the CAR unbinds from the antigen more readily. To compensate for weaker binding, a higher density of antigens is required to achieve the necessary receptor occupancy for activation.\n2.  **Dependence on $\\theta$**: The relationship with $\\theta$ is nonlinear. As $\\theta \\to 0$, $n_{\\min} \\to 0$, meaning a very low activation threshold requires very few antigens. Conversely, as $\\theta \\to 1$, the denominator $(1 - \\theta) \\to 0$, causing $n_{\\min} \\to \\infty$. This signifies that an extremely high activation threshold (requiring near-total receptor saturation) is practically impossible to achieve.\n3.  **Implications for Armored CARs**: The problem states that armored CARs can effectively lower $\\theta$. Our derivation shows that decreasing $\\theta$ directly decreases $n_{\\min}$. This is the mathematical basis for the improved efficacy of armored CARs against tumors with low antigen expression. If the antigen density $n$ on a tumor cell is such that $n_{\\min, \\text{conventional}}  n$ but $n_{\\min, \\text{armored}} \\le n$ (due to $\\theta_{\\text{armored}}  \\theta_{\\text{conventional}}$), the armored CAR will activate while the conventional one will not. To be effective against solid tumors where antigen density might be in the range of $n \\in [10^{4}, 10^{6}]$, CARs must be designed with sufficiently high affinity (low $K_D$) and/or armoring strategies (low $\\theta$) to ensure that $n_{\\min}$ is below the available antigen density on the target cells.", "answer": "$$\\boxed{\\frac{\\theta K_D}{1 - \\theta}}$$", "id": "5035133"}, {"introduction": "While sensitivity is crucial for efficacy, ensuring that CAR-T cells attack only malignant cells and spare healthy tissue is paramount for patient safety. This hands-on practice explores how advanced \"logic-gated\" CAR designs, which require the presence of two distinct antigens for activation, can dramatically improve specificity [@problem_id:5035068]. You will apply principles of probability theory to a translational scenario, modeling the risk that unavoidable assay noise could lead to false-positive activation and calculating the expected rate of off-tumor toxicity, a critical step in preclinical safety assessment.", "problem": "An engineered logic-gated Chimeric Antigen Receptor (CAR) T cell is designed to activate only when both antigen detection streams exceed predefined thresholds (an AND gate). In a translational assay development setting for clinical translation, suppose that in truly healthy tissue (no true antigen present), the per-cell measured signals for antigen $A$ and antigen $B$ on a $\\log_{10}$-fluorescence scale are dominated by assay measurement error and can be modeled as independent Gaussian random variables:\n- $X_A \\sim \\mathcal{N}(\\mu_{A0}, \\sigma_A^2)$,\n- $X_B \\sim \\mathcal{N}(\\mu_{B0}, \\sigma_B^2)$,\n\nwith parameters $\\mu_{A0} = 0$, $\\sigma_A = 0.4$, $\\mu_{B0} = 0$, and $\\sigma_B = 0.5$. The AND-gated CAR activates on a cell if and only if $X_A \\ge \\tau_A$ and $X_B \\ge \\tau_B$, with thresholds $\\tau_A = 1.2$ and $\\tau_B = 1.0$.\n\nAssuming independence of the assay errors between $A$ and $B$, and independence across cells, compute the expected number of false-positive CAR activations among $N = 10^7$ truly healthy cells. Round your answer to three significant figures. Report the expected number as a pure count (no units).", "solution": "The problem asks for the expected number of false-positive Chimeric Antigen Receptor (CAR) T cell activations in a population of $N = 10^7$ healthy cells. A false-positive activation for a single cell occurs if the measured signals for both antigen $A$ and antigen $B$ exceed their respective thresholds. This corresponds to an AND-gate logic.\n\nLet $X_A$ and $X_B$ be the random variables representing the measured log-fluorescence signals for a single cell. The problem states that in healthy tissue, these signals are modeled as independent Gaussian random variables:\n- $X_A \\sim \\mathcal{N}(\\mu_{A0}, \\sigma_A^2)$, where the mean is $\\mu_{A0} = 0$ and the standard deviation is $\\sigma_A = 0.4$.\n- $X_B \\sim \\mathcal{N}(\\mu_{B0}, \\sigma_B^2)$, where the mean is $\\mu_{B0} = 0$ and the standard deviation is $\\sigma_B = 0.5$.\n\nA false-positive activation for a single cell occurs if and only if the event $E = \\{X_A \\ge \\tau_A \\text{ and } X_B \\ge \\tau_B\\}$ happens, where the activation thresholds are given as $\\tau_A = 1.2$ and $\\tau_B = 1.0$.\n\nLet $p$ be the probability of a false-positive activation for a single cell. Due to the stated independence of the measurement errors for $A$ and $B$, the signals $X_A$ and $X_B$ are independent. Therefore, this probability is the product of the individual probabilities:\n$$p = P(E) = P(X_A \\ge \\tau_A \\text{ and } X_B \\ge \\tau_B) = P(X_A \\ge \\tau_A) \\times P(X_B \\ge \\tau_B)$$\n\nTo calculate these probabilities, we first standardize the random variables. A general Gaussian variable $X \\sim \\mathcal{N}(\\mu, \\sigma^2)$ can be transformed into a standard normal variable $Z \\sim \\mathcal{N}(0, 1)$ by the transformation $Z = \\frac{X - \\mu}{\\sigma}$. Let $\\Phi(z) = P(Z \\le z)$ be the cumulative distribution function (CDF) of the standard normal distribution. The tail probability is then $P(Z \\ge z) = 1 - \\Phi(z)$.\n\nFor the antigen $A$ signal, we compute the Z-score for the threshold $\\tau_A$:\n$$z_A = \\frac{\\tau_A - \\mu_{A0}}{\\sigma_A} = \\frac{1.2 - 0}{0.4} = 3$$\nThe probability of the signal for antigen $A$ exceeding this threshold is:\n$$P(X_A \\ge \\tau_A) = P\\left(\\frac{X_A - \\mu_{A0}}{\\sigma_A} \\ge \\frac{\\tau_A - \\mu_{A0}}{\\sigma_A}\\right) = P(Z \\ge z_A) = P(Z \\ge 3) = 1 - \\Phi(3)$$\n\nSimilarly, for the antigen $B$ signal, we compute the Z-score for the threshold $\\tau_B$:\n$$z_B = \\frac{\\tau_B - \\mu_{B0}}{\\sigma_B} = \\frac{1.0 - 0}{0.5} = 2$$\nThe probability of the signal for antigen $B$ exceeding this threshold is:\n$$P(X_B \\ge \\tau_B) = P\\left(\\frac{X_B - \\mu_{B0}}{\\sigma_B} \\ge \\frac{\\tau_B - \\mu_{B0}}{\\sigma_B}\\right) = P(Z \\ge z_B) = P(Z \\ge 2) = 1 - \\Phi(2)$$\n\nNow, we can calculate the overall single-cell false-positive probability $p$:\n$$p = P(X_A \\ge \\tau_A) \\times P(X_B \\ge \\tau_B) = (1 - \\Phi(3)) \\times (1 - \\Phi(2))$$\n\nThe problem states that activations across cells are independent. Therefore, the total number of false-positive activations, let's denote this by the random variable $Y$, in a population of $N$ cells follows a binomial distribution, $Y \\sim \\text{Binomial}(N, p)$. The expected number of false positives is the expectation of this distribution:\n$$E[Y] = N \\times p = N \\times (1 - \\Phi(3)) \\times (1 - \\Phi(2))$$\n\nWe are given $N = 10^7$. We use standard numerical values for the standard normal CDF:\n- $\\Phi(2) \\approx 0.977249868$\n- $\\Phi(3) \\approx 0.998650102$\n\nFrom these, we can find the tail probabilities:\n- $P(X_A \\ge \\tau_A) = 1 - \\Phi(3) \\approx 1 - 0.998650102 = 0.001349898$\n- $P(X_B \\ge \\tau_B) = 1 - \\Phi(2) \\approx 1 - 0.977249868 = 0.022750132$\n\nNow, we calculate $p$:\n$$p \\approx (0.001349898) \\times (0.022750132) \\approx 3.07111 \\times 10^{-5}$$\n\nFinally, we compute the expected number of false positives among the $N=10^7$ cells:\n$$E[Y] = N \\times p \\approx 10^7 \\times (3.07111 \\times 10^{-5}) \\approx 307.111$$\n\nThe problem requires the answer to be rounded to three significant figures. The value $307.111$ rounded to three significant figures is $307$.", "answer": "$$\\boxed{307}$$", "id": "5035068"}, {"introduction": "Multi-specific CARs represent a powerful strategy to counteract tumor evolution and antigen escape, but their complexity can introduce unintended and detrimental side effects. This practice models the challenge of fratricide, a phenomenon where CAR-T cells targeting a shared T-cell marker begin to kill each other, compromising the therapy's persistence and effectiveness [@problem_id:5035076]. You will synthesize concepts from receptor kinetics, stochastic processes, and genetic engineering to build a comprehensive risk model, allowing you to quantify the danger of fratricide and evaluate the impact of mitigation strategies like CRISPR-mediated gene knockout.", "problem": "A translational medicine team is developing a next-generation, multi-specific Chimeric Antigen Receptor (CAR) T cell therapy. The CAR contains two single-chain variable fragment (scFv) binding domains: one recognizes a tumor-restricted antigen ($A_{\\mathrm{tumor}}$; e.g., CD19), and the other recognizes a T cell antigen ($A_{\\mathrm{T}}$; e.g., CD7). While the tumor arm mediates desired cytotoxicity, the $A_{\\mathrm{T}}$ arm risks fratricide (self-killing among CAR T cells). You will model the fratricide risk and incorporate engineering strategies to reduce it.\n\nUse the following foundational bases:\n- Receptor-ligand occupancy under mass-action binding: the fraction of occupied CAR binding sites scales as $\\theta = \\frac{L}{L + K_D}$, where $L$ is the effective ligand level and $K_D$ is the dissociation constant.\n- Cell-cell encounters are well modeled as a Poisson process over a time window, so the probability of zero fatal events equals $\\exp(-\\lambda)$ when the mean number of fatal events is $\\lambda$.\n\nAssume the following:\n1. The effective antigen density of $A_{\\mathrm{T}}$ on CAR T cells before engineering is $D_7 = 1.0 \\times 10^{5}$ molecules per cell. The CAR’s anti-$A_{\\mathrm{T}}$ arm has an effective dissociation constant $K_D' = 7.5 \\times 10^{4}$ molecules per cell.\n2. Per cell, the T cell–T cell encounter rate driven by $A_{\\mathrm{T}}$ recognition is $\\lambda_{\\mathrm{TT}} = 0.50$ encounters per hour. Consider a time window of $\\tau = 48$ hours post-infusion.\n3. For a fully occupied synapse mediated by the $A_{\\mathrm{T}}$ arm, the baseline per-contact cytotoxic event probability is $p_0 = 0.40$.\n4. In a symmetric encounter between two CAR T cells mediated by $A_{\\mathrm{T}}$, the probability that the index CAR T cell dies in that contact is half of the per-contact cytotoxic event probability (i.e., a $1/2$ symmetry factor).\n5. Two engineering strategies are deployed:\n   - Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) knockout of $A_{\\mathrm{T}}$ on CAR T cells with efficiency $q = 0.90$, so the residual antigen density on CAR T cells is $(1 - q) D_7$.\n   - An inhibitory Chimeric Antigen Receptor (iCAR) specific for a self-marker that reduces the effective per-contact cytotoxic event probability mediated by $A_{\\mathrm{T}}$ by a fraction $\\eta = 0.80$ (that is, the multiplicative factor on $p_0$ is $\\gamma = 1 - \\eta$).\n\nUsing only the well-tested formulas stated above and scientifically justified assumptions, derive from first principles the fratricide risk $R$ for an index CAR T cell over the $\\tau$-hour window after both engineering strategies are implemented. Explicitly define the receptor occupancy that is relevant to fratricide after engineering, combine it with the modified per-contact cytotoxic probability and symmetry factor into a mean fatal-event rate, and use the Poisson model to compute $R$.\n\nRound your final numeric answer to four significant figures. Express your answer as a decimal probability with no units.", "solution": "The problem has been validated and found to be scientifically grounded, well-posed, objective, and self-contained. All necessary parameters and models for a unique solution are provided, and the context is relevant to translational medicine and immunotherapy. The problem is valid.\n\nThe objective is to calculate the fratricide risk, $R$, for an index CAR T cell over a specified time window. The risk $R$ is defined as the probability of at least one fatal event occurring. It is complementary to the probability of zero fatal events.\n$$R = 1 - P(\\text{zero fatal events})$$\nThe problem states that cell-cell encounters leading to fatal events can be modeled as a Poisson process. The probability of observing zero events over a given time interval is given by $P(\\text{zero events}) = \\exp(-\\Lambda_{fatal})$, where $\\Lambda_{fatal}$ is the mean number of fatal events expected for the index cell during that interval.\n$$R = 1 - \\exp(-\\Lambda_{fatal})$$\nThe mean number of fatal events, $\\Lambda_{fatal}$, is the product of the total number of relevant encounters and the probability of a fatal event per encounter.\n$$\\Lambda_{fatal} = (\\text{Total Encounters}) \\times (\\text{Probability of fatal event per encounter})$$\nThe total number of T cell–T cell encounters for an index cell over the time window $\\tau$ is the product of the encounter rate, $\\lambda_{\\mathrm{TT}}$, and the duration, $\\tau$.\n$$\\text{Total Encounters} = \\lambda_{\\mathrm{TT}} \\tau$$\nThe probability of a fatal event for the index cell per encounter, denoted $P_{fatal\\_per\\_contact}$, is determined by several factors which have been modified by the engineering strategies.\n\nFirst, we determine the effective antigen density that mediates fratricide. The initial antigen density of $A_{\\mathrm{T}}$ is $D_7$. CRISPR knockout reduces this density with an efficiency of $q$. The residual antigen density, which now acts as the effective ligand level $L'$, is:\n$$L' = (1 - q) D_7$$\nSecond, we calculate the receptor occupancy, $\\theta'$, for the anti-$A_{\\mathrm{T}}$ binding domain on an engaging CAR T cell. This occupancy depends on the effective ligand level $L'$ and the dissociation constant $K_D'$, according to the provided mass-action binding formula:\n$$\\theta' = \\frac{L'}{L' + K_D'} = \\frac{(1 - q) D_7}{(1 - q) D_7 + K_D'}$$\nThird, we determine the per-contact cytotoxic event probability after engineering. The baseline probability for a fully occupied synapse is $p_0$. We assume the actual probability scales linearly with receptor occupancy, giving $p_0 \\theta'$. This is further reduced by the iCAR, which introduces a multiplicative factor $\\gamma = (1 - \\eta)$. The resulting probability of a cytotoxic event in a single T-T contact is:\n$$P_{cytotoxic\\_event} = p_0 \\theta' \\gamma = p_0 \\theta' (1 - \\eta)$$\nFourth, the problem specifies a symmetric encounter where the probability of the index cell dying is half of the total per-contact cytotoxic event probability.\n$$P_{fatal\\_per\\_contact} = \\frac{1}{2} P_{cytotoxic\\_event} = \\frac{1}{2} p_0 \\theta' (1 - \\eta)$$\nNow, we can assemble the complete expression for $\\Lambda_{fatal}$:\n$$\\Lambda_{fatal} = (\\lambda_{\\mathrm{TT}} \\tau) \\times P_{fatal\\_per\\_contact} = \\lambda_{\\mathrm{TT}} \\tau \\left[ \\frac{1}{2} p_0 (1 - \\eta) \\theta' \\right]$$\nSubstituting the expression for $\\theta'$:\n$$\\Lambda_{fatal} = \\frac{1}{2} \\lambda_{\\mathrm{TT}} \\tau p_0 (1 - \\eta) \\left( \\frac{(1 - q) D_7}{(1 - q) D_7 + K_D'} \\right)$$\nWe are given the following values:\n$D_7 = 1.0 \\times 10^{5}$ molecules/cell\n$K_D' = 7.5 \\times 10^{4}$ molecules/cell\n$\\lambda_{\\mathrm{TT}} = 0.50 \\, \\mathrm{h}^{-1}$\n$\\tau = 48 \\, \\mathrm{h}$\n$p_0 = 0.40$\n$q = 0.90$\n$\\eta = 0.80$\n\nFirst, we calculate the engineered ligand density $L'$:\n$$L' = (1 - 0.90) \\times (1.0 \\times 10^{5}) = 0.10 \\times 1.0 \\times 10^{5} = 1.0 \\times 10^{4} \\, \\text{molecules/cell}$$\nNext, we calculate the receptor occupancy $\\theta'$:\n$$\\theta' = \\frac{1.0 \\times 10^{4}}{1.0 \\times 10^{4} + 7.5 \\times 10^{4}} = \\frac{1.0 \\times 10^{4}}{8.5 \\times 10^{4}} = \\frac{1}{8.5}$$\nNow, we calculate the mean number of fatal events, $\\Lambda_{fatal}$:\n$$\\Lambda_{fatal} = \\frac{1}{2} \\times (0.50 \\times 48) \\times 0.40 \\times (1 - 0.80) \\times \\left( \\frac{1}{8.5} \\right)$$\n$$\\Lambda_{fatal} = \\frac{1}{2} \\times 24 \\times 0.40 \\times 0.20 \\times \\frac{1}{8.5}$$\n$$\\Lambda_{fatal} = 12 \\times 0.08 \\times \\frac{1}{8.5} = \\frac{0.96}{8.5} \\approx 0.112941176$$\nFinally, we calculate the fratricide risk $R$:\n$$R = 1 - \\exp(-\\Lambda_{fatal}) = 1 - \\exp(-0.112941176)$$\n$$R \\approx 1 - 0.89321455 \\approx 0.10678545$$\nRounding the final answer to four significant figures, we get:\n$$R \\approx 0.1068$$\nThis represents a $10.68\\%$ probability of an engineered CAR T cell being eliminated by fratricide over the initial $48$-hour period.", "answer": "$$\\boxed{0.1068}$$", "id": "5035076"}]}